CLINICAL STUDY: HEART FAILURE
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
Donald S. Silverberg, MDa,
Dov Wexler, MDa,
David Sheps, MDa,
Miriam Blum, MDa,
Gad Keren, MDa,
Ron Baruch, MDa,
Doron Schwartz, MDa,
Tatyana Yachnin, MDa,
Shoshana Steinbruch, RNa,
Itzhak Shapira, MDa,
Shlomo Laniado, MDa and
Adrian Iaina, MDa
a Department of Nephrology and Cardiology and Congestive Heart Failure Program, Tel Aviv Medical Center, Weizman 6, Tel Aviv, Israel
Manuscript received October 13, 2000;
revised manuscript received February 12, 2001,
accepted February 19, 2001.
Reprint requests and correspondence: Dr. D. S. Silverberg, Department of Nephrology, Tel Aviv Medical Center, Weizman 6, Tel Aviv, 64239, Israel
OBJECTIVES
This is a randomized controlled study of anemic patients with severe congestive heart failure (CHF) to assess the effect of correction of the anemia on cardiac and renal function and hospitalization.
BACKGROUND
Although mild anemia occurs frequently in patients with CHF, there is very little information about the effect of correcting it with erythropoietin (EPO) and intravenous iron.
METHODS
Thirty-two patients with moderate to severe CHF (New York Heart Association [NYHA] class III to IV) who had a left ventricular ejection fraction (LVEF) of 40% despite maximally tolerated doses of CHF medications and whose hemoglobin (Hb) levels were persistently between 10.0 and 11.5 g% were randomized into two groups. Group A (16 patients) received subcutaneous EPO and IV iron to increase the level of Hb to at least 12.5 g%. In Group B (16 patients) the anemia was not treated. The doses of all the CHF medications were maintained at the maximally tolerated levels except for oral and intravenous (IV) furosemide, whose doses were increased or decreased according to the clinical need.
RESULTS
Over a mean of 8.2 ± 2.6 months, four patients in Group B and none in Group A died of CHF-related illnesses. The mean NYHA class improved by 42.1% in A and worsened by 11.4% in B. The LVEF increased by 5.5% in A and decreased by 5.4% in B. The serum creatinine did not change in A and increased by 28.6% in B. The need for oral and IV furosemide decreased by 51.3% and 91.3% respectively in A and increased by 28.5% and 28.0% respectively in B. The number of days spent in hospital compared with the same period of time before entering the study decreased by 79.0% in A and increased by 57.6% in B.
CONCLUSIONS
When anemia in CHF is treated with EPO and IV iron, a marked improvement in cardiac and patient function is seen, associated with less hospitalization and renal impairment and less need for diuretics.
|
Abbreviations and Acronyms
| | CABG | = coronary artery bypass graft | | CHF | = congestive heart failure | | CRF | = chronic renal failure | | EPO | = erythropoietin | | %Fe Sat | = percent iron saturation | | GFR | = glomerular filtration rate | | Hb | = hemoglobin | | Hct | = hematocrit | | IU | = international units | | IV | = intravenous | | LVEF | = left ventricular ejection fraction | | NYHA | = New York Heart Association | | PA | = pulmonary artery | | sc | = subcutaneous | | SOLVD | = Studies Of Left Ventricular Dysfunction |
|
This article has been cited by other articles:

|
 |

|
 |
 
K. Dimopoulos, G.-P. Diller, G. Giannakoulas, R. Petraco, A. Chamaidi, E. Karaoli, M. Mullen, L. Swan, M. F. Piepoli, P. A. Poole-Wilson, et al.
Anemia in Adults With Congenital Heart Disease Relates to Adverse Outcome.
J. Am. Coll. Cardiol.,
November 24, 2009;
54(22):
2093 - 2100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Klapholz, W. T. Abraham, J. K. Ghali, P. Ponikowski, S. D. Anker, B. Knusel, Y. Sun, S. M. Wasserman, and D. J. van Veldhuisen
The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure
Eur J Heart Fail,
November 1, 2009;
11(11):
1071 - 1077.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Anker, J. C. Colet, G. Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, T. F. Luscher, C. Mori, B. von Eisenhart Rothe, S. Pocock, et al.
Rationale and design of Ferinject(R) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia
Eur J Heart Fail,
November 1, 2009;
11(11):
1084 - 1091.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P van der Meer, H F Groenveld, J L Januzzi Jr, and D J van Veldhuisen
Erythropoietin treatment in patients with chronic heart failure: a meta-analysis
Heart,
August 15, 2009;
95(16):
1309 - 1314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J.V. McMurray, I. S. Anand, R. Diaz, A. P. Maggioni, C. O'Connor, M. A. Pfeffer, K. R. Polu, S. D. Solomon, Y. Sun, K. Swedberg, et al.
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
Eur J Heart Fail,
August 1, 2009;
11(8):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P van der Meer and D J van Veldhuisen
The authors' reply:
Heart,
August 1, 2009;
95(15):
1279 - 1279.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Schattner
The Silent Dimension: Expressing Humanism in Each Medical Encounter
Arch Intern Med,
June 22, 2009;
169(12):
1095 - 1099.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
e1 - e90.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Circulation,
April 14, 2009;
119(14):
e391 - e479.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kazory and E. A. Ross
Anemia: the point of convergence or divergence for kidney disease and heart failure?
J. Am. Coll. Cardiol.,
February 24, 2009;
53(8):
639 - 647.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Pagourelias, C. Koumaras, A. I. Kakafika, K. Tziomalos, P. G. Zorou, V. G. Athyros, and A. Karagiannis
Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?
Angiology,
February 1, 2009;
60(1):
74 - 81.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Anker and R. Toto
Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients
NDT Plus,
January 1, 2009;
2(suppl_1):
i3 - i8.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz
The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure
Journal of Pharmacy Practice,
December 1, 2008;
21(6):
420 - 423.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Adlbrecht, S. Kommata, M. Hulsmann, T. Szekeres, C. Bieglmayer, G. Strunk, G. Karanikas, R. Berger, D. Mortl, K. Kletter, et al.
Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume
Eur. Heart J.,
October 1, 2008;
29(19):
2343 - 2350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer
Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis
J. Am. Coll. Cardiol.,
September 2, 2008;
52(10):
818 - 827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Silverberg, D. Wexlerb, A. Iaina, and D. Schwartz
The role of correction of anaemia in patients with congestive heart failure: A short review
Eur J Heart Fail,
September 1, 2008;
10(9):
819 - 823.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. S. Anand
Anemia and Chronic Heart Failure: Implications and Treatment Options
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
501 - 511.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kazory and E. A. Ross
Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective
Circulation,
February 19, 2008;
117(7):
975 - 983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.H. W. Tang, W. Tong, A. Jain, G. S. Francis, C. M. Harris, and J. B. Young
Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure.
J. Am. Coll. Cardiol.,
February 5, 2008;
51(5):
569 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Ghali, I. S. Anand, W. T. Abraham, G. C. Fonarow, B. Greenberg, H. Krum, B. M. Massie, S. M. Wasserman, M.-L. Trotman, Y. Sun, et al.
Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia
Circulation,
January 29, 2008;
117(4):
526 - 535.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. O. Okonko, A. Grzeslo, T. Witkowski, A. K.J. Mandal, R. M. Slater, M. Roughton, G. Foldes, T. Thum, J. Majda, W. Banasiak, et al.
Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency: FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
103 - 112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Joyeux-Faure
Cellular Protection by Erythropoietin: New Therapeutic Implications?
J. Pharmacol. Exp. Ther.,
December 1, 2007;
323(3):
759 - 762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Toblli, A. Lombrana, P. Duarte, and F. Di Gennaro
Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1657 - 1665.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Francis and A. Kanderian
Anemia and Heart Failure: A New Pathway?
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1666 - 1667.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Joss, R. Patel, K. Paterson, K. Simpson, C. Perry, and C. Stirling
Anaemia is common and predicts mortality in diabetic nephropathy
QJM,
October 1, 2007;
100(10):
641 - 647.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. van Veldhuisen, K. Dickstein, A. Cohen-Solal, D. J.A. Lok, S. M. Wasserman, N. Baker, D. Rosser, J. G.F. Cleland, and P. Ponikowski
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
Eur. Heart J.,
September 2, 2007;
28(18):
2208 - 2216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. F. Murphy and K. McDonald
Treatment of anaemia in chronic heart failure optimal approach still unclear
Eur. Heart J.,
September 2, 2007;
28(18):
2185 - 2187.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Gregory, M. Halliday, C. Averill, N. Bhala, C. Tselepis, and T. Iqbal
Iron deficiency anaemia: further education regarding the British Society of Gastroenterology guidelines is required
Gut,
September 1, 2007;
56(9):
1319 - 1319.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Husemann, M. Fobker, M. Pohlen, C. Bruch, M. Hausberg, G. Breithardt, and H. Reinecke
Impact of haemoglobin concentration and chronic kidney disease in patients with coronary heart disease undergoing percutaneous coronary interventions
Nephrol. Dial. Transplant.,
September 1, 2007;
22(9):
2563 - 2570.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Asaumi, Y. Kagaya, M. Takeda, N. Yamaguchi, H. Tada, K. Ito, J. Ohta, T. Shiroto, K. Shirato, N. Minegishi, et al.
Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice
Circulation,
April 17, 2007;
115(15):
2022 - 2032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Komajda
Anemia in Chronic Heart Failure: Should We Treat It and How?
J. Am. Coll. Cardiol.,
February 20, 2007;
49(7):
763 - 764.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ponikowski, S. D. Anker, J. Szachniewicz, D. Okonko, M. Ledwidge, R. Zymlinski, E. Ryan, S. M. Wasserman, N. Baker, D. Rosser, et al.
Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial
J. Am. Coll. Cardiol.,
February 20, 2007;
49(7):
753 - 762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. D. Westenbrink, F. W. Visser, A. A. Voors, T. D.J. Smilde, E. Lipsic, G. Navis, H. L. Hillege, W. H. van Gilst, and D. J. van Veldhuisen
Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well
Eur. Heart J.,
January 2, 2007;
28(2):
166 - 171.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Ng Kam Chuen and R. J MacFadyen
Variable aetiologies contributing to the anaemia of systolic heart failure are important to individual patient management
Eur. Heart J.,
January 2, 2007;
28(2):
143 - 145.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. W. Dec
Anemia in Heart Failure: Time to Rethink Its Etiology and Treatment?
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2490 - 2492.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Nanas, C. Matsouka, D. Karageorgopoulos, A. Leonti, E. Tsolakis, S. G. Drakos, E. P. Tsagalou, G. D. Maroulidis, G. P. Alexopoulos, J. E. Kanakakis, et al.
Etiology of Anemia in Patients With Advanced Heart Failure
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2485 - 2489.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Lipsic, R. G. Schoemaker, P. van der Meer, A. A. Voors, D. J. van Veldhuisen, and W. H. van Gilst
Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside
J. Am. Coll. Cardiol.,
December 5, 2006;
48(11):
2161 - 2167.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam
Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors
Am J Physiol Renal Physiol,
November 1, 2006;
291(5):
F932 - F944.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Valeur, O. W. Nielsen, J. J.V. McMurray, C. Torp-Pedersen, L. Kober, and TRACE Study Group
Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction
Eur J Heart Fail,
October 1, 2006;
8(6):
577 - 584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J D Newton and I B Squire
Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure
Heart,
October 1, 2006;
92(10):
1441 - 1446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Bolger, F. R. Bartlett, H. S. Penston, J. O'Leary, N. Pollock, R. Kaprielian, and C. M. Chapman
Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1225 - 1227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Hammerman-Rozenberg, J. M. Jacobs, D. Azoulay, and J. Stessman
Aspirin prophylaxis and the prevalence of anaemia
Age Ageing,
September 1, 2006;
35(5):
514 - 517.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, G. Takemura, H. Okada, S. Miyata, R. Maruyama, L. Li, M. Higuchi, S. Minatoguchi, T. Fujiwara, and H. Fujiwara
Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure
Cardiovasc Res,
September 1, 2006;
71(4):
684 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak
Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study
Circulation,
June 13, 2006;
113(23):
2713 - 2723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-D. Tang and S. D. Katz
Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options
Circulation,
May 23, 2006;
113(20):
2454 - 2461.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Auerbach and L. Goldman
Assessing and Reducing the Cardiac Risk of Noncardiac Surgery
Circulation,
March 14, 2006;
113(10):
1361 - 1376.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. O'Meara, T. Clayton, M. B. McEntegart, J. J.V. McMurray, C. C. Lang, S. D. Roger, J. B. Young, S. D. Solomon, C. B. Granger, J. Ostergren, et al.
Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
Circulation,
February 21, 2006;
113(7):
986 - 994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Felker, W. G. Stough, L. K. Shaw, and C. M. O'Connor
Anaemia and coronary artery disease severity in patients with heart failure
Eur J Heart Fail,
January 1, 2006;
8(1):
54 - 57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P Van der Meer, E Lipsic, R. Henning, K Boddeus, J van der Velden, A. Voors, D. van Veldhuisen, W. van Gilst, R. Schoemaker, J. Leemans, et al.
Heart Failure after Myocardial Infarction--Benefit beyond Hemoglobin from Erythropoietin: Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats with Heart Failure after Myocardial Infarction
J. Am. Soc. Nephrol.,
December 1, 2005;
16(12):
3449 - 3454.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Opasich, M. Cazzola, L. Scelsi, S. De Feo, E. Bosimini, R. Lagioia, O. Febo, R. Ferrari, A. Fucili, R. Moratti, et al.
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure
Eur. Heart J.,
November 1, 2005;
26(21):
2232 - 2237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. O. Okonko, D. J. Van Veldhuisen, P. A. Poole-Wilson, and S. D. Anker
Anaemia of chronic disease in chronic heart failure: the emerging evidence
Eur. Heart J.,
November 1, 2005;
26(21):
2213 - 2214.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. George, E. Goldstein, A. Abashidze, D. Wexler, S. Hamed, H. Shmilovich, V. Deutsch, H. Miller, G. Keren, and A. Roth
Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner
Cardiovasc Res,
November 1, 2005;
68(2):
299 - 306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kosiborod, J. P. Curtis, Y. Wang, G. L. Smith, F. A. Masoudi, J. M. Foody, E. P. Havranek, and H. M. Krumholz
Anemia and Outcomes in Patients With Heart Failure: A Study From the National Heart Care Project
Arch Intern Med,
October 24, 2005;
165(19):
2237 - 2244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Clark and J. G.F. Cleland
Anemia and Chronic Heart Failure: Are We Asking the Right Questions?
Circulation,
September 20, 2005;
112(12):
1681 - 1683.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chambellan, E. Chailleux, and T. Similowski
Prognostic Value of the Hematocrit in Patients With Severe COPD Receiving Long-term Oxygen Therapy
Chest,
September 1, 2005;
128(3):
1201 - 1208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. S. Anand, M. A. Kuskowski, T. S. Rector, V. G. Florea, R. D. Glazer, A. Hester, Y. T. Chiang, N. Aknay, A. P. Maggioni, C. Opasich, et al.
Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT
Circulation,
August 23, 2005;
112(8):
1121 - 1127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G.F. Cleland, A. P. Coletta, A. L. Clark, P. Velavan, and L. Ingle
Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA
Eur J Heart Fail,
August 1, 2005;
7(5):
937 - 939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. van der Meer, E. Lipsic, R. H. Henning, K. Boddeus, J. van der Velden, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, and R. G. Schoemaker
Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction
J. Am. Coll. Cardiol.,
July 5, 2005;
46(1):
125 - 133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. George, S. Patal, D. Wexler, A. Abashidze, H. Shmilovich, T. Barak, D. Sheps, and G. Keren
Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure: Comparison With Neurohormonal and Inflammatory Markers
Arch Intern Med,
June 13, 2005;
165(11):
1304 - 1309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. H. M. Chaves, R. D. Semba, S. X. Leng, R. C. Woodman, L. Ferrucci, J. M. Guralnik, and L. P. Fried
Impact of Anemia and Cardiovascular Disease on Frailty Status of Community-Dwelling Older Women: The Women's Health and Aging Studies I and II
J. Gerontol. A Biol. Sci. Med. Sci.,
June 1, 2005;
60(6):
729 - 735.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Namiuchi, Y. Kagaya, J. Ohta, N. Shiba, M. Sugi, M. Oikawa, H. Kunii, H. Yamao, N. Komatsu, M. Yui, et al.
High Serum Erythropoietin Level Is Associated With Smaller Infarct Size in Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
May 3, 2005;
45(9):
1406 - 1412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Felker, W. A. Gattis, K. F. Adams, and C. M. O'Connor
Reply
J. Am. Coll. Cardiol.,
May 3, 2005;
45(9):
1550 - 1551.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. O. Cheng
Is There an Optimal Hematocrit Value for Cardiac Patients?
J. Am. Coll. Cardiol.,
May 3, 2005;
45(9):
1549 - 1549.
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Philipp, H. Ollmann, T. Schink, R. Dietz, F. C. Luft, and R. Willenbrock
The impact of anaemia and kidney function in congestive heart failure and preserved systolic function
Nephrol. Dial. Transplant.,
May 1, 2005;
20(5):
915 - 919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Walsh, D. B. McClelland, R. J. Lee, M. Garrioch, C. R. Maciver, F. McArdle, S. L. Crofts, I. Mellor, and for the ATICS Study Group
Prevalence of ischaemic heart disease at admission to intensive care and its influence on red cell transfusion thresholds: multicentre Scottish Study
Br. J. Anaesth.,
April 1, 2005;
94(4):
445 - 452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ishani, E. Weinhandl, Z. Zhao, D. T. Gilbertson, A. J. Collins, S. Yusuf, and C. A. Herzog
Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction
J. Am. Coll. Cardiol.,
February 1, 2005;
45(3):
391 - 399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Maiese, F. Li, and Z. Z. Chong
New Avenues of Exploration for Erythropoietin
JAMA,
January 5, 2005;
293(1):
90 - 95.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. van der Meer, E. Lipsic, R. H. Henning, R. A. de Boer, A. J.H. Suurmeijer, D. J. van Veldhuisen, and W. H. van Gilst
Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury
Eur J Heart Fail,
December 1, 2004;
6(7):
853 - 859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Fried, C. Solomon, M. Shlipak, S. Seliger, C. Stehman-Breen, A. J. Bleyer, P. Chaves, C. Furberg, L. Kuller, and A. Newman
Inflammatory and Prothrombotic Markers and the Progression of Renal Disease in Elderly Individuals
J. Am. Soc. Nephrol.,
December 1, 2004;
15(12):
3184 - 3191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Caiola and J. W. Cheng
Use of Erythropoietin in Heart Failure Management
Ann. Pharmacother.,
December 1, 2004;
38(12):
2145 - 2149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Guralnik, R. S. Eisenstaedt, L. Ferrucci, H. G. Klein, and R. C. Woodman
Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia
Blood,
October 15, 2004;
104(8):
2263 - 2268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G.M. Felker, K. F. Adams Jr, W. A. Gattis, and C. M. O'Connor
Anemia as a risk factor and therapeutic target in heart failure
J. Am. Coll. Cardiol.,
September 1, 2004;
44(5):
959 - 966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A J S Coats
Anaemia and heart failure
Heart,
September 1, 2004;
90(9):
977 - 979.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. van der Meer, A. A. Voors, E. Lipsic, T. D. J. Smilde, W. H. van Gilst, and D. J. van Veldhuisen
Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure
J. Am. Coll. Cardiol.,
July 7, 2004;
44(1):
63 - 67.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sharma, D. P Francis, B. Pitt, P. A Poole-Wilson, A. J.S Coats, and S. D Anker
Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial
Eur. Heart J.,
June 2, 2004;
25(12):
1021 - 1028.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Z. Pantilat and A. E. Steimle
Palliative Care for Patients With Heart Failure
JAMA,
May 26, 2004;
291(20):
2476 - 2482.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Silverberg, D. Wexler, M. Blum, D. Schwartz, and A. Iaina
The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure
Nephrol. Dial. Transplant.,
April 1, 2004;
19(4):
1021 - 1021.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. van der Meer, A. A. Voors, E. Lipsic, W. H. van Gilst, and D. J. van Veldhuisen
Erythropoietin in cardiovascular diseases
Eur. Heart J.,
February 2, 2004;
25(4):
285 - 291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. H. Bahlmann, K. de Groot, J.-M. Spandau, A. L. Landry, B. Hertel, T. Duckert, S. M. Boehm, J. Menne, H. Haller, and D. Fliser
Erythropoietin regulates endothelial progenitor cells
Blood,
February 1, 2004;
103(3):
921 - 926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Roger, L. P. McMahon, A. Clarkson, A. Disney, D. Harris, C. Hawley, H. Healy, P. Kerr, K. Lynn, A. Parnham, et al.
Effects of Early and Late Intervention with Epoetin {alpha} on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial
J. Am. Soc. Nephrol.,
January 1, 2004;
15(1):
148 - 156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Reinecke, T. Trey, J. Wellmann, J. Heidrich, M. Fobker, T. Wichter, M. Walter, G. Breithardt, and R. M. Schaefer
Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions
Eur. Heart J.,
December 1, 2003;
24(23):
2142 - 2150.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D B McKenzie and A J Cowley
Drug therapy in chronic heart failure
Postgrad. Med. J.,
November 1, 2003;
79(937):
634 - 642.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|